<DOC>
	<DOCNO>NCT01149642</DOCNO>
	<brief_summary>This randomise , double-blind study compare oral immunomodulatory solution placebo prevention acute severe mucositis head neck cancer patient treat surgically concomitantly radiochemotherapy . The investigator expect decrease 25 % severe acute mucositis experimental arm .</brief_summary>
	<brief_title>Randomised Study Mucositis Prevention After Radiochemotherapy Treatment Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<criteria>Epidermal carcinoma prove histologically sphere ORL ( location except nasopharynx ) . Patients tumours oral cavity , oropharynx , hypopharynx larynx treat initially surgery eligible postoperative radio chemotherapy concomitantly . NB . The patient tumours larynx hypopharynx eligible radiotherapy oropharyngeal mucosa least 54 Gy mucositis visualise without use instrument . Radiochemotherapy give postoperatively . Maximum delay 8 week operative date plan start date radiochemotherapy . Performance status ( grade OMS ) : 0 , 1 , 2 Nutritional Risk Index ≥ 83.5 No mucositis . Age : 1875 year Life expectancy ≥ 3 month . Informed consent obtain patient . Affiliation social security system . Tumour nasopharynx Mucositis Severe sepsis Treatment immunomodulators month precede inclusion ATCD allergy component Oral Impact . Parenteral nutrition inclusion Usual contraindication concomitant radiochemotherapy Patient already include another therapeutic trial involve experimental molecule Female pregnant susceptible pregnant , breastfeed . Patient use appropriate contraceptive measure treatment Persons deprive liberty guardianship Patients unable commit trial schedule geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>